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Objectives. We analyzed myocardial flow reserve (MFR) in
patients with non–insulin-dependent (type II) diabetes mellitus
(NIDDM) without symptoms and signs of ischemia.
Background. Diminished MFR in diabetes has been suggested.
However, it remains controversial whether MFR is related to
glycemic control, mode of therapy or gender in NIDDM.
Methods. Myocardial blood flow (MBF) was measured at
baseline and during dipyridamole loading in 25 asymptomatic,
normotensive, normocholesterolemic patients with NIDDM and
12 age-matched control subjects by means of positron emission
tomography and nitrogen-13 ammonia, after which MFR was
calculated.
Results. Baseline MBF in patients with NIDDM ([mean 6 SD]
74.0 6 24.0 ml/min per 100 g body weight) was comparable to that
in control subjects (73.0 6 17.0 ml/min per 100 g). However, MBF
during dipyridamole loading was significantly lower in patients
with NIDDM (184 6 99.0 ml/min per 100 g, p < 0.01) than in
control subjects (262 6 120 ml/min per 100 g), as was MFR
(NIDDM: 2.77 6 0.85; control subjects: 3.8 6 1.0, p < 0.01). A
significantly decreased MFR was seen in men (2.35 6 0.84)
compared with women with NIDDM (3.18 6 0.79, p < 0.05);
however, no significant differences were found in terms of age,
hemoglobin a1c and baseline MBF. MFR was comparable between
the diet (2.78 6 0.80) and medication therapy groups (2.76 6
0.77) and was inversely correlated with average hemoglobin A1c
for 5 years (r 5 20.55, p < 0.01) and fasting plasma glucose
concentration (r 5 20.57, p < 0.01) but not age or lipid fractions.
Conclusions. Glycemic control and gender, rather than mode of
therapy, is related to MFR in NIDDM.
(J Am Coll Cardiol 1997;30:1472–7)
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It has been widely recognized that maximal myocardial
vasodilatory capacity can decrease in accordance with the
severity of coronary stenosis (1). However, recent investiga-
tions have implicated several other factors in such alter-
ations (2–9). Maximal myocardial vasodilatory capacity has
been reported to be reduced in angiographically normal
coronary arteries, especially in patients with diabetes melli-
tus (4,5). However, most of the diabetic patients in these
studies also had systemic hypertension, and the role of
hypertension in reduced flow reserve in these patients is not
yet known. Therefore, it is uncertain whether diabetes alone
decreases maximal myocardial vasodilatory capacity or if
hypertension also has such an effect (10). Glycemic control
is important in the management of diabetes mellitus be-
cause of its possible relation to vascular complications. For
example, a linear relation between glycemic control and
microangiopathy, neuropathy or retinopathy in patients with
insulin-dependent (type I) diabetes mellitus has been re-
ported (11). Furthermore, a linear relation between the
incidence of death from coronary artery disease and glyce-
mic control in patients with non–insulin-dependent (type II)
diabetes mellitus (NIDDM) has been shown (12). However,
the relation between glycemic control and blood flow ab-
normality or maximal myocardial vasodilatory capacity in
diabetic patients has not yet been clarified.
Positron emission tomography (PET) has emerged as a new
technology to measure tissue metabolism as well as blood flow
in vivo. Because this technology can estimate maximal myo-
cardial vasodilatory capacity by evaluating myocardial flow
reserve (MFR), noninvasive investigation of blood flow abnor-
mality is now possible in patients with NIDDM.
Our study was undertaken first to determine whether MFR
is decreased in patients with NIDDM without evidence of
heart disease, hypertension or hypercholesterolemia through
evaluation with PET using nitrogen-13 (N-13) ammonia and
dipyridamole stress testing. If such a reduction was found, we
planned to further investigate whether it was related to glyce-
mic control, as determined by fasting blood sugar (glucose)
concentration (FBS) and hemoglobin A1c (HbA1c), mode of
therapy and gender in NIDDM.
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Methods
Study group. Twenty-five patients with NIDDM without
hypertension, hypercholesterolemia or a history of ischemic
heart disease (15 men, 10 women) were studied. Twelve
normolipidemic, normoglycemic asymptomatic subjects (9
men and 3 women) without a history of heart disease served as
control subjects.
The following criteria were used to diagnose NIDDM: FBS
concentration .7.3 mmol/liter (140 mg/dl) and hemoglobin
A1c .6.5% before the initiation of therapy. Fourteen patients
were being treated with diet therapy alone (diet therapy group)
and 11 were receiving oral hypoglycemic agents (sulfonylurea;
medication therapy group), and the influence of the type of
therapy on MFR was assessed. Patients treated with insulin
were excluded because the mechanism of the disease process
in insulin-dependent diabetes mellitus differs from that in
NIDDM. Caffeine intake and theophylline-containing foods or
drugs were prohibited for 24 h before the PET studies.
Table 1 summarizes the general characteristics of our study
group. There were no significant differences in terms of age,
gender, body weight, height, body mass index or blood pressure
at rest and during dipyridamole administration; heart rate at
rest and during dipyridamole loading; plasma concentration of
total cholesterol; low density lipoprotein cholesterol; high
density lipoprotein cholesterol; and plasma triglyceride con-
centration between the two groups. Plasma concentrations of
FBS and hemoglobin A1c were significantly higher in those
with NIDDM than in control subjects.
Results on the rest electrocardiogram (ECG) were normal
in all study subjects. We performed a symptom-limited tread-
mill test for all subjects. Patients with typical chest pain or
abnormal ECGs indicating myocardial ischemia were ex-
cluded. All study subjects were informed of the nature of the
study, after which they agreed to participate in the protocol,
which had been approved by the local Ethics Committee.
PET. Regional baseline myocardial blood flow (MBF) and
that during dipyridamole administration was measured using
PET and N-13 ammonia. Myocardial flow images were ob-
tained using a Headtome IV scanner (Shimadzu Corp., Kyoto,
Japan). This PET scanner has seven imaging planes; in-plane
resolution is 4.5 mm at full width at half maximum, and the
z-axial resolution is 9.5 mm at full width at half maximum.
Effective in-plane resolution is 7 mm after using a smoothing
filter. The sensitivities of the Headtome IV scanners are 14 and
24 kilocounts/s (mCi/ml) for direct and cross planes, respec-
tively.
After acquiring transmission data to correct for photon
attenuation before obtaining images, 15 to 20 mCi of N-13
ammonia was injected, and dynamic scanning with PET was
performed for 2 min and static scanning with PET for 8 min.
After waiting 45 min to allow for decay of the radioactivity of
N-13 ammonia, dipyridamole (0.56 mg/kg body weight) was
administered intravenously over 4 min. Five minutes after the
end of administration of dipyridamole, 15 to 20 mCi of N-13
ammonia was injected, and, at exactly the same time, a second
dynamic scan with PET was performed for 2 min and static
scan for 8 min. The dynamic scan was performed every 15 s
(eight times) in the 2-min period and dynamic data were
obtained for seven slices. Only one-channel ECG monitoring
in limb leads was made during the study with PET. Because
standard electrodes for precordial ECG leads can absorb
gamma X-rays, 12 lead ECGs were not obtained.
Determination of MBF and MFR. Regional MBF was
calculated basically according to the two-compartment N-13
ammonia tracer kinetic model (13,14). Briefly, the two-
compartment model contains a freely diffusible N-13 ammonia
compartment in the vascular and extravascular spaces and a
second compartment that contains the metabolically trapped
N-13 label. As shown by Krivokapitch et al. (13), the two-
compartment model uses the following formula:
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
FBS 5 plasma fasting blood sugar concentration
HbA1c 5 hemoglobin A1c
MBF 5 myocardial blood flow
MFR 5 myocardial flow reserve
NIDDM 5 non–insulin-dependent diabetes mellitus
PET 5 positron emission tomography
(tomographic)
Table 1. Clinical Characteristics of Study Patients
NIDDM Group
(n 5 25)
Control Group
(n 5 12)
Male/female 15/10 9/3
Age (yr) 58.9 6 10.4 57.7 6 12.2
Body weight (kg) 57.7 6 10.4 61.7 6 5.9
Height (cm) 161.3 6 10.9 160 6 7.00
BMI 22.2 6 2.29 23.7 6 2.5
HbA1c (%) 8.46 6 1.88* 5.7 6 0.26
FBS (mmol/liter) 9.0 6 3.0* 4.9 6 0.48
TC (mmol/liter) 5.02 6 0.58 4.96 6 0.61
HDL (mmol/liter) 1.38 6 0.40 1.19 6 0.82
TG (mmol/liter) 1.38 6 0.89 1.35 6 0.55
LDL (mmol/liter) 2.84 6 0.90 2.89 6 0.36
Rest
SBP (mm Hg) 126 6 14.1 125 6 10.1
DBP (mm Hg) 75.8 6 8.32 73.2 6 6.9
HR (beats/min) 71.8 6 10.4 73.6 6 6.7
RPP (beats/min 3 mm Hg) 9,540 6 1,633 9,173 6 1,504
Dipyridamole
SBP (mm Hg) 120 6 16.1 116 6 6.8
DBP (mm Hg) 69.9 6 13.4 74.3 6 6.9
HR (beats/min) 79.5 6 12.2 83.6 6 13.0
RPP (beats/min 3 mm Hg) 9,679 6 1,540 9,603 6 15
*p , 0.01 versus control group. Data presented are mean value 6 SD or
number of patients. BMI 5 body mass index; DBP 5 diastolic blood pressure;
FBS 5 fasting plasma blood sugar concentration; HbA1c 5 hemoglobin A1c;
HDL 5 high density lipoprotein cholesterol; HR 5 heart rate; LDL 5 low
density lipoprotein cholesterol; NIDDM 5 non–insulin-dependent diabetes
mellitus; RPP 5 rate–pressure product; SBP 5 systolic blood pressure; TC 5
total cholesterol; TG 5 triglycerides.
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dQF~t!
dt
5 2
~K1 1 MBF! 3 QF~t!
0.8
1 k2 3 QT~t! 1 MBF 3 Ca~t! , [1]
dQT~t!
dt
5
K1 3 QF~t!
0.8
2 k2 3 QT~t! , [2]
where K1 (in ml/min per g) and k2 (in min
21) represent the
forward and reverse rates for exchange between the two
compartments; QF(t) is radioactivity in the freely diffusible
space; QT(t) is radioactivity trapped in the myocardium; and
Ca(t) is blood pool radioactivity. Because N-13 metabolites are
assumed not to significantly convert back into freely diffusible
space of the N-13 ammonia during the first 90 s of data
acquisition, k2 is nearly equal to zero. In contrast, the mea-
sured concentration by the tomograph Cm(t) is
Cm~t! 5 QF~t! 1 QT~t!. [3]
According to the experimental data, the relation between
K1 and MBF is as follows (13):
K1 5 ~MBF/0.607! e~1.25/MBF! 2 MBF. [4]
The time activity curve of the left ventricular cavity was
used as an input function. Tracer spillover was corrected by
least-squares nonlinear regression analysis in our program to
calculate the MBF with the assumption that myocardial and
left ventricular radioactivity were influenced by each other.
Specifically, true radioactivity of the left ventricular cavity at
the time of t(Ca(t)true) was expressed as follows:
Ca~t!true 5 Ca~t!PET 2 C1*Cm~t!true , [5]
where Ca(t)PET is radioactivity of the left ventricular cavity
measured by PET; Cm(t)true is the true radioactivity of the
cardiac muscle; and C1 is the spillover factor, which is ex-
pressed as a percentage with the assumption that C1 (%) of the
true radioactivity of the cardiac muscle was added to the
radioactivity of the left ventricular cavity measured by PET.
Similarly, true radioactivity of cardiac muscle at the time of
t(Cm(t)true) is expressed as follows:
Cm~t!true 5 Cm~t!PET 2 C2*Ca~t!true , [6]
where Cm(t)PET is myocardial radioactivity measured by PET;
Ca(t)true is the true radioactivity of the left ventricular cavity;
and C2 is the spillover factor, which is expressed as a percent-
age with the assumption that C2 (%) of the true radioactivity of
the left ventricular cavity was added to the myocardial radio-
activity measured by PET. We determined C1, C2, MBF and
the K1 value by using equations 1 to 6 and least squares
nonlinear regression analysis.
All data were corrected for dead time effects to reduce
error to ,1%. To avoid the influence of the partial volume
effect associated with the objects’ size, the relation between
recovery coefficients and wall thickness obtained from experi-
mental phantom studies in our laboratory was determined. For
the correction of partial volume effect, wall thickness was
measured with two-dimensional echocardiography by special-
ists in our hospital. The recovery coefficients estimated by
myocardial wall thickness were taken into consideration in our
program to measure MBF. For example, the recovery coeffi-
cient was 0.8 when myocardial wall thickness was 10 mm.
MFR was determined by the ratio of MBF during dipyrid-
amole loading to baseline MBF. Regions of interest were
placed at the septum, anterior wall, lateral wall and inferopos-
terior wall on the transaxial images. Details are shown in
Figure 1. To obtain input function, regions of interest were
placed on the left ventricular cavity of each slice. To compare
MFR, the average regional MBF was used.
Statistics. Baseline MBF, MBF during dipyridamole ad-
ministration, MFR, body weight, systolic blood pressure, dia-
stolic blood pressure, height, body mass index and lipid
Figure 1. Schematic representation of placement of regions of interest
and anatomic orientation of each segment on the transaxial images.
Regions of interest were placed on the transaxial images as follows:
For each slice, the anteroapical pole (APP) was determined visually,
and a tangent to the anteroapical pole was drawn. Then a perpendic-
ular line to the tangent from the anteroapical pole (PA line) was drawn
from the anteroapical pole. The J line was drawn from the junction of
the right ventricular wall and the septum (RVSJ) to the PA line at an
angle of 45°. Based on the PA line and J line, the left ventricle was
divided into eight segments equally. Septal segments were obtained
from the middle transaxial slice (#5, #6) and lower slice (#13, #14),
and anterior segments were obtained from the middle slice (#7, #8)
and lower slice (#15, #16). Anteroseptal segments were defined as the
left anterior descending coronary artery region. The lateral wall
segment was obtained from the middle slice (#9, #10) and lower slice
(#17, #18). Lateral segments were defined as the left circumflex
coronary artery region. The inferoposterior wall segment was obtained
from the middle slice (#11, #12) and lower slice (#19, #20). When
#11, #12 of the middle slice was not large enough to place a region of
interest, those segments were excluded in the data analysis. Inferopos-
terior segments were defined as the right coronary artery region.
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variables in the two groups were compared using analysis of
variance, and then individual data were analyzed by the
two-tailed Student t test. Values are expressed as the mean
value 6 SD. A value of p , 0.05 was considered significant.
Results
Hemodynamic and ECG responses to dipyridamole infu-
sion. There were no significant differences in systolic blood
pressure at rest and during dipyridamole administration and
rate–pressure product between patients and control subjects
(Table 1). During dipyridamole administration, typical chest
pain or chest oppression accompanied by ECG changes was
not observed in any study subject. Atypical chest pain, chest
discomfort or dyspnea suggesting side effects of dipyridamole
was observed in four patients without abnormal ECG changes.
Recording 12-lead ECG during PET is problematic because
the absorbance of gamma X-rays by the standard electrodes
could possibly influence PET measurements; therefore, a
detailed description of ECG response to dipyridamole was not
possible.
Baseline MBF and MBF during dipyridamole administra-
tion. In patients with NIDDM, baseline MBF (74.0 6
24.0 ml/min per 100 g) was similar to that of control subjects
(73.0 6 17.0 ml/min per 100 g); however, it was significantly
lower during dipyridamole administration (184 6 99.0 vs.
262 6 120 ml/min per 100 g, p , 0.01). MFR was significantly
lower in patients with NIDDM (2.77 6 0.85) than in control
subjects (3.80 6 1.00, p , 0.01). A significant decrease in MFR
was seen in male (2.35 6 0.84) compared with female patients
with NIDDM (3.18 6 0.79, p , 0.05), whereas age (57.5 6 10.6
in men vs. 61.1 6 10.2 in women), HbA1c (8.4 6 1.8 in men vs.
8.7 6 2.1 in women) and baseline MBF (70.0 6 24.0 ml/min
per 100 g in men vs. 80.0 6 20.0 ml/min per 100 g in women)
were comparable between the male and female patients with
NIDDM. There was no significant regional difference in MFR
in the patients or the control subjects (Table 2).
Mode of therapy and MFR. MFR in the diet therapy group
(2.78 6 0.80) was comparable to that in the medication therapy
group (2.76 6 0.77), and MFR in both groups was significantly
lower in patients with NIDDM than in control subjects (p ,
0.01). There were no significant differences in HbA1c and age
between the diet therapy group and the medication therapy
group (HbA1c: 8.2 6 1.7 vs. 8.5 6 2.0; age: 55.8 6 10.7 vs.
61.6 6 10.4, respectively), nor were there in systolic blood
pressure (124 6 8.86 vs. 129 6 18.1 mm Hg), diastolic blood
pressure (73.6 6 9.75 vs. 76.4 6 8.29 mm Hg) and rate–
pressure product (8,586 6 1,548 vs. 9,245 6 1,470).
Relation between MFR and HbA1c, FBS and plasma lipid
fractions. MFR correlated with FBS for the previous 5 years
(r 5 20.57, p , 0.01). There was a significant inverse
correlation between MFR and average HbA1c for the previous
5 years in the entire study group (control subjects and patients
with NIDDM) (r 5 20.55, p , 0.01) (Fig. 2). However, there
was no significant correlation between MFR and plasma lipid
fractions or age and blood pressure in the entire study group.
Discussion
MFR in patients with NIDDM. Reduced maximal myocar-
dial vasodilatory capacity in diabetes as assessed by coronary
flow velocity has been reported (4,5). The existence of a
microcirculation abnormality was suggested in human diabetic
patients (4,5), as has been reported in animal experimental
studies (15–18). However, because most of the patients used in
those previous two studies had systemic hypertension, which
can decrease MFR, it remained unclear whether MFR is
typically decreased in patients with normotensive NIDDM
without evidence of myocardial ischemia. Also, in those previ-
ous studies, flow reserve was measured with a Doppler cathe-
ter, which requires arterial cannulation (4,5), thus limiting the
Table 2. Comparison of Regional Myocardial Flow Reserve
Myocardial Flow Reserve
Septum Ant Wall Lat Wall Post Wall
Control group 3.95 6 1.35* 3.84 6 1.53* 3.61 6 1.21* 3.80 6 1.33*
NIDDM group 2.92 6 0.89 2.82 6 0.92 2.57 6 0.90 2.77 6 0.87
*p , 0.01 versus NIDDM group. Data presented are mean value 6 SD.
Ant 5 anterior; Lat 5 lateral; NIDDM 5 non–insulin-dependent diabetes
mellitus; Post 5 posterior.
Figure 2. Top, Relation between MFR and FBS concentration for the
previous 5 years in the entire study groups. Bottom, Relation between
MFR and average HbA1c (%) for the previous 5 years in the entire
study groups.
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selection of study subjects. Moreover, a Doppler catheter can
only measure coronary flow velocity and cannot achieve accu-
rate measurement of MBF volume. Our selection of subjects,
as well as the method of measurement used, differentiates our
study from those previous studies.
Glycemic control is thought to be essential for the manage-
ment of diabetes. For instance, recent studies have reported a
hyperglycemia-induced angiopathy (19,20) and a linear rela-
tion between glycemic control and the incidence of death from
coronary artery disease (12). The relation between retinopa-
thy, neuropathy or nephropathy in diabetes and glycemic
control has also been reported in insulin-dependent diabetes
(11). However, it has not been clarified whether MFR is
related to glycemic control in patients with NIDDM. We found
reduced MFR without an increase in baseline MBF in such
patients, and this abnormality was related to glycemic control
and gender rather than mode of therapy. Furthermore, we
found a significant inverse relation between MFR and the
degree of long-term glycemic control in asymptomatic patients
with NIDDM.
Because increased coronary resistance (21) and an attenu-
ated response to reactive hyperemia with oral hypoglycemic
agents (22,23) have been reported, those circumstances may
influence maximal myocardial vasodilation in patients using
oral hypoglycemic agents. However, no significant difference in
flow reserve between patients on diet therapy and patients on
medication therapy was reported in seven normotensive dia-
betic patients (5). In our present study, the significant inverse
relation between MFR and long-term glycemic control sug-
gests that MBF abnormalities in NIDDM are related to the
degree of glycemic control rather than the mode of therapy.
Our results and those of other investigators indicate that
long-term glycemic control is essential for the management of
vascular complications in patients with NIDDM. Extending
these findings, the current report is the first of a relation
between glycemic control and MFR.
MFR and lipid profiles, gender and age. Reduced MFR in
patients with hyperlipidemia has been reported (8–10), as well
as significantly greater reductions in MFR in male than in
female patients with familial hypercholesterolemia (8). There-
fore, the additional influence of hyperlipidemia on MFR in
diabetes should be considered. However, in this study our
patients were normocholesterolemic, so a significant relation
between MFR and lipid levels would not be expected. We did,
however, find that MFR in NIDDM was significantly lower in
male than in female patients, and we believe that this is the first
demonstration of a gender-specific variance in MFR in diabe-
tes. Because our female study subjects were postmenopausal
(mean age 61 years), the direct effect of estrogen on MFR can
be considered negligible; however, the protective effect of
estrogen during the premenopausal years may be related to
this result. Although Czernin et al. (24) reported the influence
of age on MFR, our patients were within a narrow age range;
therefore, no correlation between age and MFR was expected
in view of the design of the study.
Possible mechanism for the reduced MFR in NIDDM.
With reference to the reports that showed diminished myocar-
dial vasodilatory capacity in human diabetes (4,5), our results
may in part be attributed to coronary microangiopathy, diffuse
macrovascular atherosclerosis, as has been suggested by Mintz
et al. (25), or abnormal endothelial function, or a combination
of these. It is acknowledged that blood flow response to
dipyridamole is considered endothelial independent. However,
animal experimental studies suggest that endothelial dysfunc-
tion might also affect blood flow response to papaverine or
dipyridamole (through flow-mediated vasodilation) (26–28).
Therefore, an impairment of flow-mediated vasodilation (en-
dothelial function) might account for this finding. In addition,
balanced multivessel macrovascular disease without flow-
limiting stenosis or differences in wall stress between patients
and control subjects might also account for this finding.
Determination of MBF with N-13 ammonia PET. To de-
termine MBF, we based our study on the two-compartment
model using PET and N-13 ammonia, because this model has
been well validated (13,14) and is frequently used in the
assessment of MBF (8,9,24,29–35). Another model reported to
measure MBF using PET and N-13 ammonia was a three-
compartment model that considered metabolites of N-13 am-
monia (36). However, animal experimental studies have shown
that metabolites of N-13 ammonia can be negated during the
first 90 s after N-13 ammonia injection (37,38). Therefore,
accuracy of the measurement of MBF with N-13 ammonia
PET and the two-compartment model is assured.
Conclusions. MFR was reduced in patients with NIDDM
without evidence of ischemia. The inverse relation between
MFR and HbA1c or FBS suggests that the degree of chronic
glycemic control might be related to blood flow abnormality in
patients with NIDDM, rather than the mode of therapy.
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